Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valacyclovir for Suppression of HSV and HIV Shedding in MSM
NCT00378976Phase 3Completed
- Sponsor
- University of Washington
- Start
- Aug 2003
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in herpes simplex (HSV) comparing Valacyclovir First with Placebo First (2 arms). Primary endpoint: Reduction in anogenital HIV-1 shedding at 18 weeks. Started Aug 2003; status: completed.
02
Drugs
valaciclovir
03
Conditions
herpes simplex (HSV)
Beyond the preview
Go deeper on NCT00378976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00378976.